He’s the F.D.A.’s Cancer Chief, Not a Fortune Teller
The New York Times
Dr. Richard Pazdur for 25 years has overseen innovations in the treatment of deadly diseases at the agency.
Twenty five years ago, cancer was almost a different disease. Despite the so-called War on Cancer, declared in 1971 by President Richard Nixon, treatments had mostly remained the same blunt instruments — brutal chemotherapy, surgery and radiation. It seemed as if cancer had won the war.
Now, cancer medicine is in a new place. An increasing array of treatments precisely target the cancer itself. And for some cancers, researchers have learned to direct the immune system to kill the malignant cells. Cures are possible for some cancers that had seemed incurable. Many patients can live longer and better lives than ever seemed possible. Cancer death rates have been plunging, and researchers attribute most of that to improved treatments.
Overseeing this change at the Food and Drug Administration has been Dr. Richard Pazdur, currently the director of the Oncology Center of Excellence. Trained as an oncologist, he leads the agency and its cancer specialists in determining how cancer drugs are tested and approved.
Through 25 years at the agency in a variety of roles, he has been present from the start of the new era and has seen firsthand how scientific discoveries completely changed the prospects for many cancer patients. In two edited and condensed conversations, he discussed what he has seen, and what he hopes for.
What was it like to be a cancer doctor when you first began, and what has changed?
When I started in medical oncology in 1979, we had less than 40 oncology drugs for all cancers. I came to the F.D.A. in 1999, thinking that most drug development would be done by the National Cancer Institute. I thought industry would have very little interest because most drugs were short course with excessive toxicity and many patients had a poor prognosis.
Donald Trump’s pledge to let Robert F. Kennedy Jr. “go wild on health” has put three issues on the agenda in the final days of the 2024 campaign.
The epidemic in Africa continues to grow, prompting fears of another outbreak in the U.S. But the vaccine is no longer free, and vulnerable people are going without.
Scientists dug up the real dirt on the substance applied to all the baseballs used in the major leagues.
In Colombia, a fossil-collecting rancher has found a giant, flightless killer from 13 million years ago — and a missing link to the region’s evolutionary history.
A team recently dived deep beneath Lake Huron hoping to harvest grain that may one day be distilled into whiskey with a flavor forgotten to history.
Museums are adding scents as another tool for communicating information about science and other subjects in their exhibits.
If every emergency room in the United States were fully prepared to treat children, thousands of lives would be saved and the cost would be $11.84 or less per child, researchers found.
The hunt for dark matter is shifting from particles to waves named after a laundry detergent.
Since the Mexico City restaurant Contramar turned a classic fish dish into a go-to entree, versions have popped up from Milwaukee to Greece.
Breaking up the C.D.C., moving funds from the N.I.H. — conservatives have floated changes should Mr. Trump regain office.
The ghosts of stars are up to their usual mischief.